NCT05703126

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Recruiting now NA Last updated 5 November 2024

What this trial tests

NA trial testing History taking in Acute Myeloid Leukemia, Adult in 100 participants. Currently enrolling.

Timeline

1 December 2022

Primary endpoint
1 January 2025

3 August 2025

Quick facts

Lead sponsor	Samara State Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	100
Start date	1 December 2022
Primary completion	1 January 2025
Estimated completion	3 August 2025
Sites	1 location across Russia

Drugs / interventions tested

• History taking
• Anthropometry
• Complete blood count
• Biochemical blood test
• Coagulogram
• Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine
• Stress echocardiography with the definition of global longitudinal deformation of the myocardium
• Triplex scanning of neck vessels
• Electrocardiography
• Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes
• Cytogenetic examination of the bone marrow to determine genetic abnormalities.
• Cytological examination of bone marrow cells with cytochemical examination
• Immunophenotypic examination of the bone marrow by flow cytometry
• Determination of the presence of a FLT3 mutation using the PCR Method
• laser Doppler flowmetry

Conditions studied

• Acute Myeloid Leukemia, Adult — all drugs for Acute Myeloid Leukemia, Adult →
• Cardiotoxicity — all drugs for Cardiotoxicity →
• Endothelial Dysfunction — all drugs for Endothelial Dysfunction →

Sponsor

Samara State Medical University

Who can join

Adults 18 to 65, any sex, with Acute Myeloid Leukemia, Adult or Cardiotoxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of immature myeloid cells.

Anthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s. However, the clinical usefulness of anthracyclines is limited primarily by the high incidence of cardiotoxicity. According to the European Society of Cardiology guidelines for cardio-oncology, cardiovascular toxicity is defined as any impairment of cardiac function associated with anticancer treatment, as the term encompasses both a wide range of possible clinical manifestations and an etiological relationship with various treatments, including chemotherapy, radiation therapy, immunotherapy and treatment with targeted drugs. Cardiovascular toxicity can be acute, subacute or delayed, manifesting many years after chemotherapy or radiation therapy, involving a number of cardiac structures, which can lead to the development of heart failure, coronary heart disease, valvular heart disease, arrhythmias, including cardiac conduction disorders and diseases of the pericardium.

Anthracycline-induced cardiotoxicity is the negative effect of anthracyclines on normal cardiac activity due to their toxic effects on the heart muscle and the cardiac conduction system. Anthracycline-induced cardiotoxicity manifests as asymptomatic left ventricular dysfunction in 57% of treated patients and restrictive or dilated cardiomyopathy leading to congestive heart failure (CHF) in 16% to 20% of patients. Anthracycline-induced congestive heart failure is often resistant to therapy and has a mortality rate of up to 79%. Thus, there is a need for early detection of cardiovascular dysfunction associated with chemotherapy treatment of acute myeloid leukemia in order to timely prescribe drug therapy.

Purpose of the study To optimize the early detection of endothelial dysfunction and left ventricular myocardial contractility in patients with acute myeloid leukemia during chemotherapy treatment based on a comprehensive assessment of instrumental and laboratory research parameters.

Expected results Based on a comprehensive analysis using laser Doppler flowmetry, stress echocardiography with the determination of global longitudinal strain of the myocardium, biochemical markers of endothelial damage and cardiac biomarkers, a correlation between violations of the contractility of the left ventricular myocardium and violations of the vasoregulatory function of the vascular endothelium will be revealed, which will allow developing an algorithm for early detection of cardiomyopathy and vascular complications in patients with acute myeloid leukemia during chemotherapy treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.